Drug Trial Radar · NCT05580588
Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas
Last checked: Nov 19, 2026Latest source record: Jun 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
14
Actual
Start
Aug 31, 2023
Primary completion
Oct 4, 2024
Study completion Oct 31, 2024
Sponsor
- Lead sponsor
- Shanghai Pharma Biotherapeutics USA Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 14, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study SPH4336-US-01 is an open-label (no placebo), multicenter clinical trial to evaluate the safety, blood levels (pharmacokinetics) and preliminary anti-tumor effects of SPH4336, a selective enzyme blocker, in patients with specific types of liposarcomas (tumors expressing the target of the study drug).
Conditions
- Liposarcoma, Dedifferentiated
Interventions
SPH4336Drug
400 mg SPH4336 PO QD
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS) at 12 WeeksTime frame: 12 weeks
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Mayo Clinic Hospital
Phoenix, Arizona
City of Hope
Duarte, California
Mayo Clinic Florida
Jacksonville, Florida
University of Miami
Miami, Florida
University of Michigan
Ann Arbor, Michigan
Hackensack University Medical Center
Hackensack, New Jersey
Seidman Cancer Center, University Hospitals
Cleveland, Ohio
The Ohio State University
Columbus, Ohio
Vanderbilt University Medical Center
Nashville, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.